Cue Biopharma is a biopharmaceutical company engineering a class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body. Co. uses the modular nature of the Immuno- Selective Targeting and Alteration of T Cells (STAT) platform to design drug product candidates for selective immune modulation in cancer, chronic infectious disease, and autoimmune disease. Co. has developed four biologic series within the Immuno-STAT platform: CUE-100, CUE-200, CUE-300, and CUE-400, each specifically designed through rational engineering to possess signaling modules for desired biological mechanisms that may be applied across various diseases. The CUE stock yearly return is shown above.
The yearly return on the CUE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CUE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|